Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism

Antiviral Research

Volumn 111, Issue , 2014, Pages 8-12

  Pilorgé, Léa ^a,b   Burrel, Sonia ^c,d,e   Aït Arkoub, Zaïna ^e   Agut, Henri ^c,d,e   Boutolleau, David ^c,d,e  

^a UNIVERSITÉ DE BREST   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

DNA polymerase inhibitors; Human cytomegalovirus; Natural polymorphism; Resistance to; Terminase complex

Indexed keywords

AMINO ACID; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; HUMAN CYTOMEGALOVIRUS TERMINASE COMPLEX; NUCLEOTIDE; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA; VIRUS ENZYME; ANTIVIRUS AGENT; DEOXYRIBONUCLEASE; TERMINASE; UL56 PROTEIN, CYTOMEGALOVIRUS; UL89 PROTEIN, CYTOMEGALOVIRUS; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CODON; CYTOMEGALOVIRUS INFECTION; DNA POLYMORPHISM; DRUG APPROVAL; ENZYME SUBUNIT; FEMALE; GENE SEQUENCE; GENETIC CODE; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CLASSIFICATION; CYTOMEGALOVIRUS; DRUG EFFECTS; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; VIROLOGY;

HUMAN HERPESVIRUS 5;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; ENDODEOXYRIBONUCLEASES; HUMANS; PHYLOGENY; POLYMORPHISM, GENETIC; VIRAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 84907481766     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.08.014     Document Type: Article

References (22)

1. E. Bogner Human cytomegalovirus terminase as a target for antiviral chemotherapy Rev. Med. Virol. 12 2002 115 127
2. E.M. Borst, K. Wagner, A. Binz, B. Sodeik, and M. Messerle The essential human cytomegalovirus gene UL52 is required for cleavage-packaging of the viral genome J. Virol. 82 2008 2065 2078
3. E.M. Borst, J. Kleine-Albers, I. Gabaev, M. Babic, K. Wagner, A. Binz, I. Degenhardt, M. Kalesse, S. Jonjic, R. Bauerfeind, and M. Messerle The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89 J. Virol. 87 2013 1720 1732
4. D. Boutolleau, C. Deback, C. Bressollette-Bodin, S. Varnous, N. Dhedin, B. Barrou, J.P. Vernant, I. Gandjbakhch, B.M. Imbert-Marcille, and H. Agut Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection Antiviral Res. 81 2009 174 179
5. D. Boutolleau, S. Burrel, and H. Agut Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir Antiviral Res. 91 2011 32 35
6. G. Champier, S. Hantz, A. Couvreux, S. Stuppfler, M.C. Mazeron, S. Bouaziz, F. Denis, and S. Alain New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modeling of the catalytic site DEXDc Antivir. Ther. 12 2007 217 232
7. G. Champier, A. Couvreux, S. Hantz, A. Rametti, M.C. Mazeron, S. Bouaziz, F. Denis, and S. Alain Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity Antivir. Ther. 13 2008 643 654
8. R.F. Chemaly, A.J. Ullmann, S. Stoelben, M.P. Richard, M. Bornhäuser, C. Groth, H. Einsele, M. Silverman, K.M. Mullane, J. Brown, H. Nowak, K. Kölling, H.P. Stobernack, P. Lischka, H. Zimmermann, H. Rübsamen-Schaeff, R.E. Champlin, G. Ehninger, and AIC246 Study Team Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation N. Engl. J. Med. 370 2004 1781 1789
9. S. Chou, N.S. Lurain, A. Weinberg, G.Y. Cai, P.L. Sharma, C.S. Crumpacker, and Adult AIDS Trials Group CMV Laboratories Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance Antimicrob. Agents Chemother. 43 1999 1500 1502
10. A. Dittmer, J.C. Drach, L.B. Townsend, A. Fischer, and E. Bogner Interaction of the putative cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides J. Virol. 79 2005 14660 14667
11. A.M. Fillet, L. Auray, S. Alain, S. Gourlain, B.M. Imbert, F. Najioullah, G. Champier, S. Gouarin, J. Carquin, N. Houhou, I. Garrigue, A. Ducancelle, D. Thouvenot, and M.C. Mazeron Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between III and I Antimicrob. Agents Chemother. 48 2004 1865 1868
12. T. Goldner, G. Hewlett, N. Ettischer, H. Ruebsamen-Schaeff, H. Zimmermann, and P. Lischka The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase J. Virol. 85 2011 10884 10893
13. T. Goldner, C. Hempel, H. Ruebsamen-Schaeff, H. Zimmermann, and P. Lischka Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure Antimicrob. Agents Chemother. 58 2014 610 613
14. D.R. Kaul, S. Stoelben, E. Cober, T. Ojo, E. Sandusky, P. Lischka, H. Zimmermann, and H. Ruebsamen-Schaeff First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246 Am. J. Transplant. 11 2001 1079 1084
15. G. Komazin, L.B. Townsend, and J.C. Drach Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides J. Virol. 78 2004 710 715
16. P.M. Krosky, M.R. Underwood, S.R. Turk, K.W. Feng, R.K. Jai, R.G. Ptak, A.C. Westerman, K.K. Biron, L.B. Towsend, and J.C. Drach Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56 J. Virol. 72 1998 4721 4728
17. P. Lischka, and H. Zimmermann Antiviral strategies to combat cytomegalovirus infections in transplant recipients Curr. Opin. Pharmacol. 8 2008 541 548
18. P. Lischka, G. Hewlett, T. Wunberg, J. Baumeister, D. Paulsen, T. Goldner, H. Ruebsamen-Schaeff, and H. Zimmermann In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246 Antimicrob. Agents Chemother. 54 2010 1290 1297
19. N.S. Lurain, and S. Chou Antiviral drug resistance of human cytomegalovirus Clin. Microbiol. Rev. 23 2010 689 712
20. M. Marschall, T. Stamminger, A. Urban, S. Wildum, H. Ruebsamen-Schaeff, H. Zimmermann, and P. Lischka In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (Letermovir) against herpesviruses and other human pathogenic viruses Antimicrob. Agents Chemother. 56 2012 1135 1137
21. J. Reefschlaeger, W. Bender, S. Hallenberger, O. Weber, P. Eckenberg, S. Goldmann, M. Haerter, I. Buerger, J. Trappe, J.A. Herrington, D. Haebich, and H. Ruebsamen-Waigmann Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action J. Antimicrob. Chemother. 48 2001 757 767
22. S. Stoelben, W. Arns, L. Renders, J. Hummel, A. Mühlfeld, M. Stangl, M. Fischereder, W. Gwinner, B. Suwelack, O. Witzke, M. Dürr, D. Beelen, D. Michel, P. Lischka, H. Zimmermann, H. Ruebsamen-Schaeff, and K. Budde Pre-emptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study Transpl. Int. 27 2014 77 86